T-Knife

T-knife is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor (TCR). A promising modality that holds the potential to generate transformational responses in patients with solid tumors.

News

Key Facts

Sector: Life Sciences
Country: Germany
Fund: LSP 6
Entry: 2021
Website: https://www.t-knife.com/
EQT Responsible Advisor: Christoph Broja
Website: T-Knife

A close-up 3D rendering of a red cancer cell with intricate structures.

A close-up 3D rendering of a red cancer cell with intricate structures.

News

April 7, 2026
EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
January 12, 2026
EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases
January 12, 2026
EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics
October 22, 2025
EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics

Do You Want to Know More?

We are eager to explore how we can achieve great things together.